- Home
- Blog
- News
- Basics
- Sources
- Agencies, Regulatory & Organisations
- CERSI Excipients Browser
- Excipient Report
- Excipient DMF List
- EXCiPACT Certified Companies
- Excipient Documentation
- Excipient EINECS Numbers
- Excipient E-Numbers
- FDA Inactive Ingredient List
- FDA GRAS Substances (SCOGS) Database
- IPEC Americas
- USP - U.S. Pharmacopeia
- Definitions
- Whitepapers / Publications
- Supplier
- Services
- Media
- Events
- 1st pharmaexcipients Poster Award
- Event Calendar
- Events featured by pharma-excipients
- 4th Annual Formulation & Drug Delivery Congress
- DDF Summit
- ExcipientFest Americas
- ExcipientFest Asia
- Global CompliancePanel
- International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
- Formulation & Drug Delivery USA Congress
- Laboratory Medicine 2018
- Making Pharmaceuticals Europe
- Making Pharmaceuticals Exhibition
- Pharma Integrates
- PharmaExcipients China @CPhI China
- TTC Technology Training Center
- Jobs
- Online Sourcing
- Contact
23. May 2015
The purpose of this study was to conduct a head-to-head comparison of different solubility-enabling formulations, and their consequent solubility–permeability interplay. The low-solubility anticancer drug etoposide was formulated in several strengths of four solubility-enabling formulations: hydroxypropyl-β-cyclodextrin, the cosolvent polyethylene glycol 400 (PEG-400), the surfactant sodium lauryl sulfate, and an amorphous solid dispersion formulation......